Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 4, 2011, Pages

  Winkfield, Karen M ^a,b   Chen, Ming Hui ^c   Dosoretz, Daniel E ^d   Salenius, Sharon A ^d   Katin, Michael ^d   Ross, Rudi ^d   D'Amico, Anthony V ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d 21ST CENTURY ONCOLOGY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiac comorbidity; Prostate brachytherapy; Prostate cancer; Racial disparities; Treatment outcomes

Indexed keywords

COMORBIDITY; PROSTATE BRACHYTHERAPY; PROSTATE CANCERS; RACIAL DISPARITIES; TREATMENT OUTCOMES;

EPIDEMIOLOGY; ONCOLOGY; RADIOTHERAPY;

DISEASES;

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CAUCASIAN; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; FOLLOW UP; GLEASON SCORE; HEART INFARCTION; HISPANIC; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RACE DIFFERENCE;

ADENOCARCINOMA; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; CAUSE OF DEATH; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HISPANIC AMERICANS; HUMANS; MALE; MYOCARDIAL INFARCTION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 80155137270     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.02.022     Document Type: Article

References (38)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2008 CA Cancer J Clin 58 2 2008 71 96 (Pubitemid 351521864)
2. A. Farkas, D. Schneider, M. Perrotti, K.B. Cummings, and W.S. Ward National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening Urology 52 3 1998 444 448 discussion 448-449
3. L.A. Gloeckler Ries, M.E. Reichman, D.R. Lewis, B.F. Hankey, and B.K. Edwards Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program Oncologist 8 6 2003 541 552 (Pubitemid 37467370)
4. J.A. Eastham, and M.W. Kattan Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer J Urol 163 1 2000 143 145
5. J.W. Moul, I.A. Sesterhenn, and R.R. Connelly Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men JAMA 274 16 1995 1277 1281
6. I.J. Powell, M. Banerjee, and M. Novallo Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease Urology 55 2 2000 246 251 (Pubitemid 30069925)
7. C.A. Pettaway, P. Troncoso, E.I. Ramirez, D.A. Johnston, L. Steelhammer, and R.J. Babaian Prostate specific antigen and pathological features of prostate cancer in black and white patients: A comparative study based on radical prostatectomy specimens J Urol 160 2 1998 437 442 (Pubitemid 29476693)
8. W.A. Sakr, G.P. Haas, B.F. Cassin, J.E. Pontes, and J.D. Crissman The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients J Urol 150 Pt 2 1993 379 385 (Pubitemid 23215874)
9. W. Dale, S. Vijayakumar, E.F. Lawlor, and K. Merrell Prostate cancer, race, and socioeconomic status: inadequate adjustment for social factors in assessing racial differences Prostate 29 5 1996 271 281 (Pubitemid 26372599)
10. G.J. Tarman, C.J. Kane, and J.W. Moul Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system Urology 56 6 2000 1016 1020
11. S. Vijayakumar, R. Weichselbaum, F. Vaida, W. Dale, and S. Hellman Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status Cancer J Sci Am 2 4 1996 225 233
12. R.J. Hamilton, W.J. Aronson, and J.C. Presti Jr. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database Cancer 110 10 2007 2202 2209 (Pubitemid 350100741)
13. C.K. Cross, D. Shultz, and S.B. Malkowicz Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate J Clin Oncol 20 12 2002 2863 2868 (Pubitemid 34651515)
14. M. Roach III, J. Lu, M.V. Pilepich, S.O. Asbell, M. Mohiuddin, and D. Grignon Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials J Urol 169 1 2003 245 250 (Pubitemid 35461598)
15. L. Holmes Jr., W. Chan, Z. Jiang, D. Ward, E.J. Essien, and X.L. Du Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer Cancer Control 16 2 2009 176 185
16. M.J. Schymura, A.R. Kahn, and R.R. German Factors associated with initial treatment and survival for clinically localized prostate cancer: Results from the CDC-NPCR Patterns of Care Study (PoC1) BMC Cancer 10 2010 152
17. United States Census Bureau. Median household income by zip code. Available at http://factfinder.census.gov/servlet/SAFFFacts. Accessed December 1, 2010.
18. O. Beahrs, D. Henson, and R. Hutter American Joint Commission on Cancer: Manual for staging cancer 4th ed. 1992 JB Lippincott Philadelphia
19. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 11 1998 969 974 (Pubitemid 28445094)
20. D. Cox Regression models and life-tables J R Stat Soc Ser B Methodol 34 1972 187 220
21. W.R. Lee, A.F. deGuzman, R.L. Bare, M.G. Marshall, and D.L. McCullough Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution Int J Radiat Oncol Biol Phys 46 1 2000 83 88 (Pubitemid 30021484)
22. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
23. L.A. Cupples, D.R. Gagnon, R. Ramaswamy, and R.B. D'Agostino Age-adjusted survival curves with application in the Framingham Study Stat Med 14 16 1995 1731 1744
24. L.N. Lee, C. Barnswell, T. Torre, P. Fearn, M. Kattan, and L. Potters Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: Multivariate and matched-pair analyses Int J Radiat Oncol Biol Phys 53 2 2002 282 289 (Pubitemid 34522094)
25. W.L. Barrett, W.M. Kassing, and R. Shirazi Efficacy of brachytherapy for prostate cancer in African Americans compared with Caucasians Brachytherapy 3 1 2004 30 33 (Pubitemid 38521158)
26. M. Heron, D.L. Hoyert, S.L. Murphy, J. Xu, K.D. Kochanek, and B. Tejada-Vera Deaths: Final data for 2006 Natl Vital Stat Rep 57 14 2009 1 134
27. I. Cheng, J.S. Witte, and L.A. McClure Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California Cancer Causes Control 2009 1431 1440
28. D. Martinez-Tyson, E.B. Pathak, H. Soler-Vila, and A.M. Flores Looking under the Hispanic umbrella: Cancer mortality among Cubans, Mexicans, Puerto Ricans and other Hispanics in Florida J Immigr Minor Health 11 4 2009 249 257
29. D. McGee, R. Cooper, Y. Liao, and R. Durazo-Arvizu Patterns of comorbidity and mortality risk in blacks and whites Ann Epidemiol 6 5 1996 381 385 (Pubitemid 26375173)
30. J.L. Beebe-Dimmer, N.L. Nock, and C. Neslund-Dudas Racial differences in risk of prostate cancer associated with metabolic syndrome Urology 74 1 2009 185 190
31. J.A. Chirinos, A. Veerani, and J.P. Zambrano Evaluation of comorbidity scores to predict all-cause mortality in patients with established coronary artery disease Int J Cardiol 117 1 2007 97 102 (Pubitemid 46402941)
32. J.R. Ouellette, D.G. Small, and P.M. Termuhlen Evaluation of Charlson-age comorbidity index as predictor of morbidity and mortality in patients with colorectal carcinoma J Gastrointest Surg 8 8 2004 1061 1067 (Pubitemid 39600649)
33. C.M. Tammemagi, C. Neslund-Dudas, M. Simoff, and P. Kvale In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival J Clin Epidemiol 57 6 2004 597 609 (Pubitemid 38891497)
34. A. Nanda, M.H. Chen, M.H. Braccioforte, B.J. Moran, and A.V. D'Amico Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 8 2009 866 873
35. P.L. Nguyen, M.H. Chen, and T.K. Choueiri Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size Int J Radiat Oncol Biol Phys 2011 1318 1322
36. K. Winkfield, and M. Albert Unanswered questions regarding the effect of androgen deprivation therapy for prostate cancer on cardiovascular disease risk in black men Curr Cardiovascular Risk Rep 4 4 2010 311 317
37. M.D. Wong, M.F. Shapiro, W.J. Boscardin, and S.L. Ettner Contribution of major diseases to disparities in mortality N Engl J Med 347 20 2002 1585 1592 (Pubitemid 35315840)
38. M. Putt, J.A. Long, and C. Montagnet Racial differences in the impact of comorbidities on survival among elderly men with prostate cancer Med Care Res Rev 66 4 2009 409 435